Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Napro Biotherap(npro) -- Ignore unavailable to you. Want to Upgrade?

To: mwj6 who wrote (401)	9/18/2000 12:04:12 PM
From: caly	Read Replies (1) \| Respond to of 478

Thanks for the heads up with those links. Today's news... Monday September 18, 11:27 am Eastern Time Press Release NaPro BioTherapeutics Files Patent Infringement Suit Relating to TAXOL Against Bristol-Myers Squibb Corporation BOULDER, Colo.--(BW HealthWire)--Sept. 18, 2000--NaPro BioTherapeutics, Inc. (Nasdaq: NPRO - news) today announced that it has filed a patent infringement suit, together with its licensee, Abbott Laboratories (NYSE: ABT - news), in the United States District Court for the District of Colorado against Bristol-Myers Squibb Corporation (NYSE: BMY - news). The suit alleges infringement of U.S. Patent numbers 5,972,992 and 5,977,164 which relate to paclitaxel, the active ingredient in Bristol-Myers Squibb's anticancer drug, TAXOL®. NaPro BioTherapeutics, Inc., headquartered in Boulder, Colorado, with additional manufacturing and plantation operations in British Columbia, Canada, is a biopharmaceutical company focused on the development, production and licensing of complex natural-product pharmaceuticals